Zusammenfassung
Aripiprazol ist ein atypisches Antipsychotikum mit einer etwa 30 %igen intrinsischen
dopaminagonistischen Aktivität. Zusätzlich wirkt Aripiprazol als ein 5-HT1A-Agonist und 5-HT2A-Antagonist und wird daher auch als Dopamin-Serotonin-Stabilisator bezeichnet. Kontrollierte
Studien ergaben eine Wirksamkeit bei akutem Rezidiv schizophrener Psychosen, bei chronischen
Schizophrenien sowie bei schizoaffektiven Störungen. Aripiprazol zeigte sich effektiv
sowohl in der Behandlung produktiv-psychotischer Symptome als auch in der Behandlung
der Negativsymptomatik. Im Vergleich zu anderen Antipsychotika zeigte Aripiprazol
ein günstiges Nebenwirkungsprofil mit geringer Gewichtszunahme, geringer extrapyramidal-motorischer
Symptomatik, keiner signifikanten Prolaktinerhöhung sowie unauffälligen QTc-Werten.
Die Wirksamkeit in der Langzeitbehandlung schizophrener Psychosen scheint vergleichbar
mit anderen Antipsychotika (z. B. Olanzapin) zu sein. Die Zulassung in Deutschland
wird für die Behandlung der schizophrenen und schizoaffektiven Störungen für das Jahr
2004 erwartet. Die ersten Auswertungen zu Studien zum Einsatz von Aripiprazol bei
der bipolaren Manie zeigten eine signifikante Wirksamkeit.
Abstract
Aripiprazole is an atypical antipsychotic agent with an intrinsic dopamineagonist
activity of 30 %. Aripiprazole exerts additional partial agonist action on 5-HT1A receptors and has antagonist properties at 5-HT2A receptors. Controlled studies demonstrated an effectiveness in acute relapse of schizophrenic
psychosis, chronical schizophrenic and schizoaffective disorders. Aripiprazole was
effective in the treatment of productive psychotic and negative symptoms. Compared
to other antipsychotics aripiprazole demonstrated a favourable profile of side effects:
only slight changes of body weight, mild extrapyramidal symptoms, no prolactin elevation
and no significant changes in QTc interval. The efficacy in the long term treatment
of schizophrenia seems to be similar to other antipsychotics (e. g. olanzapine). The
first evaluations of studies with patients with bipolar disorders showed a significant
efficacy in the treatment of mania.
Literatur
- 1
Wolf S S, Hyde T M, Weinberger D R.
Neurobiology of schizophrenia.
Curr Opin Neurol Neurosurg.
1993;
6 (1)
86-92
- 2
Bennett M R.
Monoaminergic synapses and schizophrenia: 45 years of neuroleptics.
J Psychopharmacol.
1998;
12 (3)
289-304
- 3
Krystal J H, D'Souza D C, Sanacora G, Goddard A W, Charney D S.
Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety
disorders.
Med Clin North Am.
2001;
85 (3)
559-577
- 4
Naber D, Lambert M, Krausz M, Haasen C.
Atypische Neuroleptika in der Behandlung schizophrener Patienten.
Uni med-Verlag.
2002;
2. erweiterte Auflage
26-44
- 5
Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S.
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone
(OPC-14 597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor
agonistic activity and postsynaptic D2 receptor antagonistic activity.
J Pharmacol Exp Ther.
1995;
274 (1)
329-336
- 6
Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tattori K, Uwahodo Y, Nishi T.
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis
and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3 - 4-dihydro-2(1H)-quinolinone
derivatives.
J Med Chem.
1998;
41 (5)
658-667
- 7
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan A S, Dannals R F, Ravert H, Suri A,
Bramer S, Wong D F.
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic
drug aripiprazole (OPC 14 597): a study using positron emission tomography and [11C]Raclopride.
Neuropsychopharmacology.
2002;
27 (2)
248-259
- 8
Stahl S M.
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics,
part 2: illustrating their mechanism of action.
J Clin Psychiatry.
2001;
62 (12)
923-924
- 9
Burris K D, Molski T F, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca F D, Molinoff P B.
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine
D2 receptors.
J Pharmacol Exp Ther.
2002;
302 (1)
381-389
- 10
Grady M A, Gasperoni T L, Kirkpatrick P.
Aripiprazole.
Nat Rev Drug Discov.
2003;
2 (6)
427-428
- 11
Shapiro D A, Renock S, Arrington E, Chiodo L A, Liu L X, Sibley D R, Roth B L, Mailman R.
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Neuropsychopharmacology.
2003;
28 (8)
1400-1411
- 12
Tamminga C A, Carlsson A.
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis.
Curr Drug Target CNS Neurol Disord.
2002;
1 (2)
141-147
- 13
Crismon M L, DeLeon A, Miller A L.
Aripiprazole: does partial dopaminergic agonism translate in clinical benefits?.
Ann Pharmacother.
2003;
37 (5)
738-740
- 14
Keck Jr P E, McElroy S L.
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Expert Opin Investig Drugs.
2003;
12 (4)
655-662
- 15
Petrie J L, Saha A R, McEvoy J P.
Aripiprazole, a novel antipsychotic: phase 2 clinical trial result.
Eur Neuropsychopharmacol.
1997;
7 (Suppl 2)
S 227
- 16
Daniel D G, Saha A R, Ingenito G. et al .
Aripiprazole, a novel antipsychotic: overview of the phase II study result.
Int J Neuropsychopharmacol.
2000;
3 (Suppl 1)
157
- 17
Mallikaarjun S, Tammara B K, Salazar D E. et al .
The effects of hepatic impairment on the pharmocokinetics of aripiprazole [abstract
no. TPII-91].
Clin Pharmacol Ther.
2002;
71 (2)
66-157
- 18
Mallikaarjun S, Ali M W, Salazar D E. et al .
The effects of age and gender on the pharmocokinetics of aripiprazole [abstract no.
TPII-90].
Clin Pharmacol Ther.
2002;
71 (2)
66-157
- 19
Potkin S G, Saha A R, Kujawa M J, Carson W H, Ali M, Stock E, Stringfellow J, Ingenito G,
Marder S R.
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs
placebo in patients with schizophrenia and schizoaffective disorder.
Arch Gen Psych.
2003;
60 (7)
681-690
- 20
Kane J M, Carson W H, Saha A R, McQuade R D, Ingenito G, Zimbroff D L, Ali M.
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with
schizophrenia and schizoaffective disorder.
J Clin Psychiatry.
2002;
63 (9)
763-771
- 21
Marder S R, McQuade R D, Stock E, Kaplita S, Marcus R, Safferman A Z, Ali M, Iwamoto T.
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term
placebo-controlled trials.
Schizophr Res.
2003;
61 (2 - 3)
123-136
- 22
Schmauss M, Medori R, Kungel M, Saha A R, McQuade R.
Metaanalyse der Wirksamkeit von Aripiprazol.
Der Nervenarzt.
2002;
Suppl 1
191
- 23
Casey D E, Carson W H, Saha A R, Liebeskind A, Ali M, Jody D, Ingenito G.
Switching patients to aripiprazole from other antipsychotic agents: A multicenter
randomized study.
Psychopharmacology.
2003;
166 (4)
391-399
- 24
Medori R, Kungel M, Saha A R, Kujawa M.
Umstellung auf eine Monotherapie mit Aripiprazol.
Der Nervenarzt.
2002;
Suppl 1
191
- 25 Kujawa M, Saha A R, Ingenito G, Ali M. et al .Aripiprazole for long-term maintenance
treatment of schizophrenia [Poster]. Montreal: XXIII CINP Congress 2002 Jun 23 - 27
- 26 Kujawa M, Saha A, Ingenito G, Ali M. et al .Aripiprazole for long-term maintenance
treatment of schizophrenia. Philadelphia: APA Annual Meeting 2002: 376-157
- 27 Carson W, Pigot T, Saha A R. et al .Aripiprazole vs Placebo in the treatment of
stable, chronic schizophrenia [Poster]. Montreal: XXIII CINP Congress 2002: Jun 23
- 27
- 28 Cornblatt B, Kern B, Carson W. et al .Neurocognitive effects of aripiprazole vs
olanzapine in stable psychosis [Poster]. Montreal: XXIII CINP Congress 2002: Jun 23
- 27
- 29
Marcus R, Saha A R, Jody D, Tourkodimitris S, Archibald D, Iwamoto T.
Aripiprazole versus placebo in acute mania.
European Neuropsychopharmacology. Supplement-3 .
2002;
12
289
- 30
Keck Jr P E, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A R, Ingenito G.
A plazebo-controlled, double-blind study of the efficacy and safety of aripiprazole
in patients with acute bipolar mania.
Am J Psychiatry.
2003;
160 (9)
1651-1658
- 31 Young A. Acute treatment of manic episodes: the role of atypical antipsychotics.
Third international expert review of bipolar disorders. München 6. - 8.09.2003
- 32
Sajatovic M.
Treatment for mood and anxiety disorders: quietiapine and aripiprazole.
Curr Psychiatry Rep.
2003;
5 (4)
320-326
- 33
Riedel M, Medori R, Kungel M, Saha A R, McQuade R.
Langzeitwirksamkeit und Verträglichkeit von Aripiprazol.
Der Nervenarzt.
2002;
Suppl 1
190
- 34
McGavin J, Goa K.
Aripiprazole.
CNS Drugs.
2002;
16 (11)
779-788
- 35
Woods S W.
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
J Clin Psychiatry.
2003;
64
663-667
- 36
Gründer G, Wong D F.
Die nächste Generation „atypischer” Antipsychotika: der Beitrag der Positronenemissionstomographie.
Fortschr Neurol Psychiatr.
2003;
71 (8)
415-420
- 37
Bandelow B, Meier A.
Aripirazole, a “Dopamine-Serotonin System Stabilizer” in the treatment of psychosis.
German J Psychiatry.
2003;
6
9-16
- 38
Riedel M, Strassing M, Kühn K U, Müller N, Möller H J.
Aripiprazol.
Psychopharmakotherapie.
2003;
2
46-54
Dr. med. Barbara Fischer
Rheinische Kliniken Essen · Klinik für Psychiatrie und Psychotherapie der Universität
Duisburg-Essen
Virchowstr. 174
45147 Essen
